metsera novo nordisk - Search News

Pfizer, Novo Nordisk and Metsera

Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits

NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk.

· 6d · on MSN

Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

· 2d · on MSN

Novo Nordisk gives up battle for Metsera as Pfizer inks $10B deal

PharmExec

Novo Nordisk Not Planning Increased Proposal Offer After Metsera Enters $10 Billion Amended Merger Agreement with Pfizer

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

10h

Novo Nordisk: Buy This Bargain

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.

Big Danish drugmaker Novo Nordisk (NVO 3.88%) reported its third-quarter results on Wednesday, Nov. 5. Although sales and earnings grew year over year, the company downgraded its ...

STAT

FTC raises concern about Novo Nordisk attempt to acquire obesity startup Metsera

The Federal Trade Commission has raised concerns about Novo Nordisk’s attempt to outbid Pfizer to acquire obesity startup ...

Novo Nordisk trims outlook as obesity drug maker loses ground to Eli Lilly

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results